ProCE Banner Activity

Modern Management of Advanced Pancreatic Cancer: Expert Answers to Frequently Asked Questions, Edition 2

Text Module

Expert answers to frequently asked questions about modern clinical management of pancreatic cancer, including diagnosis and screening, neoadjuvant treatment, first-line and second-line therapy, and novel approaches such as combining immunotherapy with chemotherapy or radiation.

Released: January 02, 2018

Expiration: January 01, 2019

No longer available for credit.

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Milind Javle

Milind Javle, MD

Professor, Tenure Track
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dan Laheru

Dan Laheru, MD

Associate Professor
Department of Oncology/Medical Oncology
Johns Hopkins University, School of Medicine
Oncologist
Department of Oncology/Medical Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, Maryland

Kenneth Yu

Kenneth Yu, MD, MSc

Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor, Weill Cornell Medical College
New York, New York
Adjunct Assistant Professor
Department of Pharmacology
University of Pennsylvania
Philadelphia, Pennsylvania
Clinical Fellow
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Celgene

Halozyme

Merrimack

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with pancreatic cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current guidelines and clinical findings to select individualized therapies for patients with newly diagnosed advanced pancreatic cancer
  • Plan treatment strategies for patients with advanced pancreatic cancer after progression on first-line systemic therapy based on available data and treatment guidelines
  • Manage disease-related and treatment-related symptoms for patients with advanced pancreatic cancer

Program Director Disclosure

Program Director

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from Celgene, Genentech, and Merrimack.

Faculty Disclosure

Primary Author

Milind Javle, MD

Professor, Tenure Track
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Milind Javle, MD, has no real or apparent conflicts of interest to report.

Dan Laheru, MD

Associate Professor
Department of Oncology/Medical Oncology
Johns Hopkins University, School of Medicine
Oncologist
Department of Oncology/Medical Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, Maryland

Dan Laheru, MD, has no real or apparent conflicts of interest to report.

Kenneth Yu, MD, MSc

Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor, Weill Cornell Medical College
New York, New York
Adjunct Assistant Professor
Department of Pharmacology
University of Pennsylvania
Philadelphia, Pennsylvania
Clinical Fellow
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York

Kenneth Yu, MD, MSc, has disclosed that he has received consulting fees from Halozyme, Ipsen, and Merrimark and funds for research support from Halozyme.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Additional Information

Program Medium

This program has been made available online.

Participation in this self-study activity should be completed in approximately hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 02, 2018, through January 01, 2019:

1. Register online at httpProgram Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve participants’ competence in implementing strategies to screen, diagnose, and cure diverse populations of individuals infected with HCV in the United States.

Goal


The goal of this activity is to improve participants’ competence in treating patients with pancreatic cancer.